Gri bio (nasdaq: gri) reports third quarter 2023 financial results and provides corporate update

Phase 2a biomarker study of gri-0621 for idiopathic pulmonary fibrosis (“ipf”) on track to start before year end 2023; interim data expected h1 2024

GRI Ratings Summary

GRI Quant Ranking